<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunophenotypic analysis can identify protein <z:chebi fb="0" ids="53000">epitopes</z:chebi> in non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL) that may respond to targeted immunotherapies, such as anti-CD20 and anti-CD52 </plain></SENT>
<SENT sid="1" pm="."><plain>Recent studies suggest additional targets may provide therapeutic benefits in NHL </plain></SENT>
<SENT sid="2" pm="."><plain>This study evaluated protein expression of CD25, CD52, CD74 and CD80 in paediatric NHL to determine possible targets for immune-based therapeutic approaches </plain></SENT>
<SENT sid="3" pm="."><plain>Patient samples were derived from paediatric NHL clinical trials sponsored by the Children's <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Group (CCG, now the Children's <z:hpo ids='HP_0002664'>Oncology</z:hpo> Group, COG) and included Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>), diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), disseminated T- and B-cell lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (T-LBL and B-LBL) and anaplastic large cell (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Immunophenotypic studies were performed on formalin-fixed, paraffin-embedded diagnostic tissues </plain></SENT>
<SENT sid="5" pm="."><plain>CD25 was expressed in 8% of T-LBL and 75% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> cases, but not in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, or B-LBL </plain></SENT>
<SENT sid="6" pm="."><plain>CD52 was expressed in 99% of cases of paediatric NHL of <z:hpo ids='HP_0000001'>all</z:hpo> subtypes </plain></SENT>
<SENT sid="7" pm="."><plain>CD74 was expressed in 100% of B-LBL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, but was absent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e> and T-LBL </plain></SENT>
<SENT sid="8" pm="."><plain>CD80 was expressed in 12% of B-LBL, 6% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and 10% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> cases studied, but was not detected in T-cell NHL </plain></SENT>
<SENT sid="9" pm="."><plain>These expression patterns suggest that CD25, CD52 and CD74 may represent potential new therapeutic targets in paediatric NHL </plain></SENT>
</text></document>